Elbute 400 Tablet contains Ethambutol 400mg, a first-line anti-tuberculosis agent widely used in combination therapy for active TB management. It works by inhibiting mycobacterial cell wall synthesis, effectively reducing bacterial load in pulmonary and extrapulmonary tuberculosis.
The 400mg dosage is suitable for adult patients and is commonly prescribed alongside other anti-TB drugs to prevent resistance and ensure comprehensive treatment. Its efficacy and tolerability make it a mainstay in TB therapy protocols.
For hospitals, TB clinics, and pharmaceutical distributors, Elbute 400 Tablet is a high-demand anti-TB product, regularly stocked in outpatient TB departments, public health programs, and specialty respiratory care centers. Continuous TB treatment programs ensure steady orders and consistent market demand.
Adding Elbute 400 Tablet to your portfolio strengthens your respiratory and infectious disease segment, opening opportunities in hospital supply chains, pharmacy distribution, institutional tenders, export markets, and third-party manufacturing. Its clinical importance and wide usage make it a valuable and reliable product for pharmaceutical distributors.